James M. Eudicone, MS, MBA

home / authors / james-m-eudicone-ms-mba

Articles

April 8th 2019

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”

Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Kelly F. Bell, PharmD, MSPhr Devin M. Enhoffer, PharmD Keith Latham, PharmD Jennifer B. Green, MD

The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.

April 14th 2018

A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

Huan Huang, PhD Kelly F. Bell, PharmD, MSPhr Ray Gani, PhD Cathy W. Tugwell, RN, BSN James M. Eudicone, MS, MBA Michelle R. Krukas-Hampel, MA

April 14th 2018

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population

Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Kelly F. Bell, PharmD, MSPhr Devin M. Enhoffer, PharmD Keith Latham, PharmD Jennifer B. Green, MD

April 14th 2018

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population

Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Kelly F. Bell, PharmD, MSPhr Devin M. Enhoffer, PharmD Keith Latham, PharmD Jennifer B. Green, MD

April 14th 2018

Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes

Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Sepehr Farahbakhshian, MS Carrie McAdam-Marx, PhD, MSCI, RPh

December 22nd 2011

Adjunctive Aripiprazole for Depression: Predictive Value of Early Assessment

David J. Muzina, MD Jessie S. Chambers, PhD Trixia A. Camacho, PharmD James M. Eudicone, MS, MBA Robert A. Forbes, PhD Robert M. Berman, MD Ross A. Baker, PhD

In treatment of depression with adjunctive aripiprazole, early improvement (week 2) was a significant predictor of remission, and lack of improvement was associated with nonremission.